Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.

Sy SKB, Chia YL, Gordi T, Hoch U, Eldon MA.

Cancer Chemother Pharmacol. 2018 May;81(5):897-909. doi: 10.1007/s00280-018-3562-3. Epub 2018 Mar 21.

2.

Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy.

Singh P, Rong H, Gordi T, Bosley J, Bhattacharya I.

Clin Transl Sci. 2016 Dec;9(6):302-310. doi: 10.1111/cts.12420. Epub 2016 Oct 4.

3.

Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.

Custodio JM, Gordi T, Zhong L, Ling KH, Ramanathan S.

J Clin Pharmacol. 2016 Jun;56(6):723-32. doi: 10.1002/jcph.657. Epub 2015 Dec 21.

PMID:
26449283
4.

Pharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry.

Gordi T, Baillie R, Vuong le T, Abidi S, Dueker S, Vasquez H, Pegis P, Hopper AO, Power GG, Blood AB.

J Clin Pharmacol. 2014 Sep;54(9):1031-7. doi: 10.1002/jcph.327. Epub 2014 May 20.

PMID:
24805288
5.

Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms.

Cowles VE, Gordi T, Hou SY.

Clin Drug Investig. 2012 Sep 1;32(9):593-601. doi: 10.2165/11634520-000000000-00000.

PMID:
22775354
6.

Drug discovery and development: lessons from an undeveloped drug.

Gordi T.

Expert Rev Clin Pharmacol. 2012 Mar;5(2):157-62. doi: 10.1586/ecp.11.76.

PMID:
22390558
7.

Artemisinin derivatives with long elimination half-life.

Gordi T.

J Pharm Pharmacol. 2008 Oct;60(10):1277-8. doi: 10.1211/jpp/60.10.0002. No abstract available.

PMID:
18812019
8.

Clinical development of metformin extended-release tablets for type 2 diabetes: an overview.

Schwartz SL, Gordi T, Hou E, Cramer M, Heritier M, Cowles VE.

Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1235-43. doi: 10.1517/17425255.4.9.1235.

PMID:
18721117
9.

Artesunate for malaria.

Gordi T.

N Engl J Med. 2008 Jul 17;359(3):313; author reply 314-5. No abstract available.

PMID:
18642414
11.

Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen.

Obua C, Hellgren U, Ntale M, Gustafsson LL, Ogwal-Okeng JW, Gordi T, Jerling M.

Br J Clin Pharmacol. 2008 Apr;65(4):493-501. doi: 10.1111/j.1365-2125.2007.03050.x. Epub 2008 Feb 20.

12.

Comments on "Dual effects of rifampin on the pharmacokinetics of atrasentan".

Gordi T.

J Clin Pharmacol. 2007 Sep;47(9):1181; author reply 1182. No abstract available.

PMID:
17766702
13.

Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.

Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, Belardinelli L, Kerensky RA.

J Nucl Cardiol. 2007 Jul;14(4):514-20.

PMID:
17679059
14.

Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.

Gordi T, Blackburn B, Lieu H.

J Clin Pharmacol. 2007 Jul;47(7):825-33.

PMID:
17585115
15.
16.

A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.

Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H.

Clin Pharmacokinet. 2006;45(12):1201-12.

PMID:
17112296
17.

Are currently deployed artemisinins neurotoxic?

Adjei GO, Goka BQ, Kurtzhals JA, Gordi T.

Toxicol Lett. 2006 Dec 1;167(2):162-4; author reply 165-6. Epub 2006 Sep 12. No abstract available.

PMID:
17049764
18.
19.

CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations.

Xie R, Tan LH, Polasek EC, Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens DJ, Arakawa T, Knuth DW, Antal EJ.

J Clin Pharmacol. 2005 Mar;45(3):352-6. No abstract available.

PMID:
15703370
20.

Supplemental Content

Loading ...
Support Center